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Abstract: In type 1 diabetes, there is a lack of insulin production and in type 2, diabetes resistances to the  
effects of insulin are predominant.  Both type 1 and type 2 have the same long-term complications. Diabetes 
effects zinc homeostasis in many ways, although it is most probably the hyperglycemia which is responsible for the 
increased urinary loss and decreases in total body zinc. The role of Zn deficiency exacerbates the  
cytokine-induced damage in the autoimmune attack which destroys the islet cell in type 1 diabetes, is unclear. 
Since Zn plays a clear role in the synthesis, storage and secretion of insulin as well as conformational integrity of 
insulin in the hexameric form, the decreased Zn, which affects the ability of the islet cell to produce and secrete 
insulin in type 2 diabetes. Oxidative stress and cellular dysfunction in diabetes may be related to increased  
intracellular oxidants and free radicals associated with decrease in intracellular Zn and in Zn dependent antioxidant 
enzymes. There appears to be a complex interrelationship between Zn and both type 1 and type 2 diabetes. Zn 
plays a key role in the cellular antioxidative defense. Dysfunctional zinc signaling is associated with a number of 
chronic disease states including cancer, cardiovascular disease, Alzheimer’s disease, and diabetes. Cellular  
homeostasis requires mechanisms that tightly control the uptake, storage, and distribution of zinc. This is achieved 
through the coordinated actions of zinc transporters and metallothioneins. 
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INTRODUCTION 
It  is  not  always  clear  which  comes  first:  the  
effects  of diabetes mellitus and hyperglycemia on zinc 
metabolism or the effects that follow alterations in 
Zn  homeostasis on carbohydrate metabolism. There 
are several forms of disordered glucose metabolism 
which are referred to collectively as diabetes. While all 
diabetes mellitus syndromes have in common some 
degree of hyperglycemia, the hyperglycemia is a 
symptom, not the metabolic error itself (Brange and 
Langkjoer, 1993). Zinc is an essential trace element 
that is indispensable for its role in maintaining normal 
physiological function and cellular homeostasis (Little 
et al., 2010). Type I diabetes mellitus has been called 
“juvenile” diabetes since it most often occurs in  
children and young adults, but it is clear that an individual 
of any age can develop this metabolic error. The current 
nomenclature for this form of diabetes is “insulin 
dependent diabetes mellitus (IDDM), type I. This 
form of energy generation results in the production 
of ketone bodies and organic acids, primarily acetoacetic 
and beta hydroxybutyric acids, with the consequence of 
the development of severe metabolic acidosis. This 
results in the typical picture of diabetic ketoacidosis 
(DKA). These patients are dependent on insulin for 
life, not just control of the blood glucose level. In 
general, a dose sufficient to replace the normal production 
of insulin will result in acceptable normalization of the 
blood glucose. This is approximately 20 to 25 units 
per day. 
The metabolic errors in type II diabetes are markedly 
different from those observed in type I diabetes. This 
disorder has been referred to as “adult” onset of  
diabetes. Type II may be seen in children and young 
adults, although it is uncommon. This was seen often 
enough, however, to have been given a name of its 
own-“Maturity onset diabetes of youth (MODY)” 
-syndrome standing for. No matter the age, in type II 
diabetes the pancreatic islet cells are capable of  
making large quantities of insulin, at least at the 
beginning of the disease (Arquilla et al., 1978).  In the 
healthy normal individual, insulin binds to a cell  
membrane receptor and, through several pathways, 
results in the transport of glucose across the membrane. 
The intracellular events associated with the activation 
of glucose transport after the signal from the insulin 
-receptor complex is received are called the “post 
-receptor” events. To a great extent, it is the failure of 
the post-receptor events that results in hyperglycemia 
in and of itself. In response to the hyperglycemia, the 
pancreatic islets produce greater and greater quantities 
of insulin which results in a “down regulation” of the 
number of insulin receptors on the cell membrane, 
which compounds the problem (Arthur and Chausmer 
1998). This results in both hyperglycemia and hyperinsulinemia. 
Additionally, the beta cells cannot make enough  
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insulin to normalize the glucose, suggesting an error in 
the ability of the beta cell to synthesize insulin. As the 
disease progresses, there may be an exhaustion of the 
beta cells with a relative inability to keep up with the 
needs for insulin production. The resultant decrease in 
insulin produced results in even greater hyperglycemia. 
In type II diabetes there is plenty of insulin, it just 
doesn’t work very well, and the islets cannot produce 
enough insulin to compensate. There is no intracellular 
starvation and no ketoacidosis. In type II diabetes, 
oral medications can improve the cellular sensitivity 
to insulin and increase insulin release. If an adequate 
response cannot be obtained with these compounds, 
exogenous insulin may be required to normalize the 
blood glucose, but these patients are not dependent on 
insulin for existence as are the type I diabetics. Since 
these patients are resistant to insulin, the daily dose of 
insulin necessary to approximate normalization of 
the blood glucose is significantly higher than the  
average daily production. In these patients, therapeutic 
doses of insulin in addition to the endogenously  
produced insulin generally range from 50 to 200 units 
per day as compared to the 20 to 30 units per day  
produced by a normal individual (Levine et al., 1983). 
Pregnancy may frequently be associated with disorders 
of glucose metabolism resulting in gestational diabetes.  
Since both hyperglycemia and hyperinsulinemia are 
detrimental to the fetus, very close control of the 
blood glucose during pregnancy is required. Women 
who  have had gestational diabetes may go on to become 
overtly diabetic after pregnancy, may never have any 
problem with glucose metabolism other than when 
pregnant, or may be “normal” for many years before 
developing diabetic symptoms. Because insulin is a 
powerful growth factor and can be produced by the 
fetal pancreas in response to high levels of maternal 
blood glucose, prolonged maternal hyperglycemia 
can result in macrosomia, or large/heavy for gestational 
age, babies, congenital fetal abnormalities and spontaneous 
abortion/miscarriage. Because of the serious complications 
associated with both the hyperglycemic and hyperinsulinemic 
states, the diagnostic criteria for gestational diabetes 
are considerably more stringent than for other forms 
of diabetes. A lesser degree of hyperglycemia is necessary 
for the diagnosis of gestational diabetes and the level 
of control of the hyperglycemia with exogenous insulin 
during pregnancy is much -“tighter’’- (Raz et al., 
1988). 
ZINC AND INSULIN INTERACTIONS 
Insulin is secreted by the beta cell both tonically (at a 
constant low level release rate) and as a high  level 
spike in response to an immediate glucose load such 
as a meal. Long before there was any biochemical 
evidence for the relationship between zinc and insulin 
in the beta cell, it was clear that the addition of zinc to 
insulin would change the time course of the effect of a 
given dose of insulin. Insulin is produced by the beta 
cell of the pancreatic islets as a single chain  
peptide that is bent around itself and linked by two 
inter-chain disulfide bonds. This proinsulin is 
cleaved by the removal of an intracellular chain  
fragment known as the “C-peptide” to form two  
peptide chain (alpha and beta) molecules of 51 
amino acids cross-linked to each other by inter-chain 
disulfide bonds. This is the insulin monomer. In the 
presence of zinc within the cell, insulin monomers 
assemble to a dimeric form for storage and secretion as 
the zinc crystal (Arthur and Chausmer 1998). Zalewski 
(1994) reported that high concentrations of glucose and 
other secretagogues decrease the islet cell labile Zn 
and video fluorescence analysis showed Zn  
concentrated in the islet cells was related to the  
synthesis, storage and secretion of insulin (Zalewski 
et al., 1994). 
In vitro, in the presence of zinc and at neutral pH, 
dimeric insulin assembles further into a hexamer 
consisting of three dimeric units. This form of insulin 
is relatively stable and it is this hexameric crystal 
which is the commonly used pharmacologic form. 
Changes in the tertiary conformation of the hexamer 
may also result in significant biologically important 
changes relating to release rate and consequent  
biologic activity (Brader and Dunn, 1991; Brange and 
Langkjoer, 1993).  In vitro data suggest that insulin 
binds to isolated liver membranes to a greater extent 
and that there is less degradation when Zn is  
co-administered with insulin (Arquilla et al., 1978). 
Zinc has three major biological roles: catalytic,  
structural and regulatory (Chasapis et al., 2011). The 
catalytic and structural role of zinc is well recognized, 
and there are many noteworthy reviews on these  
functions (Maret , 2011 and Lu and Fu 2007) and  
references therein). For example, zinc is a structural 
constituent in numerous proteins, including growth 
factors, cytokines, receptors, enzymes, and transcription 
factors belonging to cellular signaling pathways 
(Fukada et al., 2011). Moreover, it is implicated in 
numerous cellular processes as a cofactor for an  
estimated 3000 human proteins including enzymes, 
nuclear factors, and hormones (Andreini et al., 2006). 
Therapeutic interventions to alter the zinc insulin  
interactions have also been attempted. With the  
development of genetic - “engineering,”- it has  
become possible to develop analogues of insulin 
which do not form Zn insulin hexamers which result in 
a more rapid absorption from the injection site ( Garg 
et al., 1994) .  
EFFECTS OF DIABETES ON ZINC  
METABOLISM 
The predominant effect on zinc homeostasis of diabetes is 
hypozincemia which may be the result of hyperzincuria or 
decreased gastrointestinal absorption of Zn or both. It 
appears tha t  the hyperzincuria, at least, is a result 
more of hyperglycemia than any specific effect of endogenous 
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or exogenous insulin on the renal tubule. In 20 age/sex 
matched controls and 30 diabetic patients, the serum 
Zn was approximately 40% lower in the diabetes 
group. No differences within the diabetes group were 
observed when treatment differences between insulin, 
oral hypoglycemic agent or combination or between 
type I and type II diabetes were evaluated (Garg et 
al., 1994). Isbir et al. (1994) demonstrated a 20%  
decrease in serum in type I diabetes, apparently the 
result of hyperzincuria (Isbir et al., 1994). El Yazigi et 
al (1993) evaluated both type I and II diabetics and 
found the absolute and creatinine corrected excretions 
were greater in diabetics than in matched controls and 
found a positive correlation between Zn excretion 
and hemoglobin Alc concentrations. Study suggests 
that insulin treatment of diabetes may reduce the  
hyperzincuria while oral agents had no effect on the 
increased zinc excretion seen in type II diabetes 
(Honnorat et al., 1992). These data suggest hyperglycemia 
as the basis for the hyperzincuria, but since type I and 
type II patients were taking insulin or oral hypoglycemic 
agents which increase insulin secretion, an effect of 
insulin itself has not been eliminated. There is loss of a 
large amount of zinc from the body via the urine. The 
source of the zinc that is excreted remains incompletely 
resolved. There is a concurrent hypozincemia and a 
decrease in tissue zinc stores, but it is not clear if this 
is a result of the hyperzincuria or an independent 
event related to the effect of insulin or hyperglycemia 
on loss of Zn from the tissue stores with a resultant 
loss of zinc to the plasma from where it is excreted 
with a net loss of total body zinc and eventual hypozincemia. 
It has  been  postulated  that  hyperglycemia  interferes  
with  the active transport of Zn back into the renal 
tubular cells. In dogs, at least, experimentally induced 
hyperglycemia resulted in significant hyperzincuria (Kinlaw 
et al., 1983). In rats made diabetic by streptozo-tocin 
(STZ), who therefore do not have any genetic code for 
the metabolic defects seen in diabetes, increased zinc 
excretion has been routinely observed. Administration 
of insulin with reduction in the hyperglycemia reduces, 
but does not appear to completely ameliorate the  
hyperzincuria (Lau and Failla, 1984; Failla and 
Gardil, 1985). 
Alc and urinary Zn excretion.  Hemoglobin Alc is a 
reliable quantitative indicator of long-term hyperglycemia. 
In a study of 175 patients with both Type I and II  
diabetes, there was a positive correlation between urinary 
zinc excretion and hemoglobin Alc (El-Yazigi et al., 
1983). In a group of age/sex matched diabetic and normal 
subjects, cellular loss of zinc was documented from 
granulocytes as a marker for intracellular zinc status 
for the body in general in otherwise healthy  
individuals. Plasma Zn was 17% lower in the diabetic 
group than the control group but intra-cellular Zn 
differences did not reach statistical significance  
suggesting that the renal effects may be predominant 
in the eventual production of total body Zn depletion 
in diabetes (Williams et al., 1995). While hyperzincuria 
is almost uniformly found in diabetes, decreases in 
tissue. McNair et al., (1981) confirmed hyperzincuria 
in relationship to the degree of hyperglycemia, but not 
glycosuria. These studies, however, have not demonstrated 
hypozincemia in the presence of reproducible hyperzincuria 
and the authors suggest that tissue and plasma zinc 
losses via the urine may be ameliorated by a compensatory  
increase in gastrointestinal absorption of zinc. Other 
data, however, have suggested that there is also a  
defect in zinc absorption associated with hyperglycemia 
or diabetes. Kinlaw et al., (1983) demonstrated abnormal 
Zn tolerance tests in diabetic patients suggestive of 
decreased absorption. Escobar et al., (1995) also  
demonstrated a down regulation of fractional Zn 
transport which may be related to increased production 
of metallothionein in diabetics.  Metallothionein is an 
intracellular cation binding protein which appears to 
act as, among other things, an inhibitor of Zn transport. 
This decrease in gastrointestinal absorption, coupled 
with hyperzincuria, could account for significant loss of 
intracellular Zn. 
The effects of hyperinsulinism/hyperglycemia on  
tissue concentrations are difficult to evaluate. Cordova 
(1994) found increased tissue Zn in liver, muscle and 
kidney in strep- tozotocin diabetic rats. These are the 
tissues that are responsive to insulin in terms of  
glucose transport.  When the rats were exercised, 
which allows insulin independent glucose transport in 
muscle, tissue Zn decreased suggesting zinc may be 
lost from cells as glucose is translocated into muscle. 
Other studies also suggest that these same tissues  
increase zinc concentrations in the diabetic state 
( Levine et al., 1983; Failla and Gardil, 1985) .  
Conflicting data was demonstrated in another  
approach to the tissue/zinc question in the spontaneous 
diabetic sand rat animal model. Unlike the STZ  
diabetes model in which there is no genetic  
component, these rats may have a different mechanism 
for cellular responses to insulin and hyperglycemia. In 
these animals, hyperglycemia/hyperinsulinemia was 
associated with reduced tissue zinc in liver, kidney 
and muscle. Again, it should be noted that these are 
tissues in which insulin affects glucose metabolism. 
There were no changes in bone zinc (Raz et al., 
1988). Serum and urinary zinc levels were evaluated 
in patients with diabetes, congestive heart failure and 
both states. No differences in serum zinc levels were 
observed in any group, but hyperzincuria was greater 
in the group with both states than with either diabetes 
or congestive heart failure alone. Renal function, as 
evaluated by serum creatinine, was not different  
between the groups (Golik et al., 1993). 
It is clear that urinary excretion of Zn is markedly  
increased in individuals with diabetes, if hyperglycemia 
is the primary etiology, replacement with oral Zn  
supplementation should provide sufficient treatment. 
High dose supplementation in Type I diabetics and 
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normal individuals was evaluated by serum and urine 
zinc and mononuclear cell Zn concentrations. Zinc 
excretion and mononuclear zinc concentrations  
increased by a similar amount in both groups 
(Cunningham et al., 1994). 
EFFECTS OF ZINC ON DIABETES  
MELLITUS (PRIMARY DISEASE EFFECTS) 
Quarterman et al., ( 1 9 6 6 )  demonstrated that diet 
induced zinc deficiency in rats resulted in a decrease in 
the ability of the pancreas to secrete insulin in  
response to a glucose load a hallmark of diabetes. 
Boquist et al., (1968)  demonstrated  a  decrease  in  
glucose  tolerance  with  no change  in  insulin   
production  in  zinc  deficient  hamsters  in response to 
an increase glucose load. This suggested at least two 
roles for zinc: an inhibition of the post insulin  
receptor intracellular events which results in a  
decreased glucose tolerance, and a relative decrease 
in insulin secretion, since the elevated glucose should 
produce a more exuberant insulin response.  This 
suggests that zinc deficiency also reduced the ability 
of the pancreas to respond appropriately. Decreased 
granulation of the islet cell with both light and  
electron microscopy in zinc deficiency. Since zinc is 
intrinsic to the storage granulization of insulin within 
the beta cell  and  increased  insulin  secretion   
reduces  beta  cell  zinc concentration, these data are 
compatible  with decreased islet cell insulin content 
in zinc deficiency states (Engelbart and Kief, 1970). 
The etiology of Type I diabetes is the result of  
autoimmune attack on the beta cell with subsequent 
destruction of the cell. One proposed mechanism by 
which immune processes damage cells is through 
cytokine mediated induction of intracellular oxidizing 
agents, particularly free radicals. A similar  
mechanism is involved in the cell damage that occurs 
in the tissues associated with the “complications” of 
diabetes, particularly the retina in retinopathy. These 
oxidizing agents include free radicals, which have 
unpaired electrons, such as superoxide radicals, 
alkoxyl and peroxyl radicals,  hydrogen peroxide, and 
lipid peroxides. Because zinc is a necessary factor in a 
variety of “antioxidant” enzymes, particularly superoxide 
dismutase, catalase and peroxidase, al- terations of 
zinc metabolism such that adequate zinc is unavailable 
for these enzymes might be expected to contribute to 
the tissue damage observed in diabetes (Sumovski et 
al., 1992). 
Cytokines are one of the mediators of the immune  
response; they are potential candidates as the  
mediators of cell destruction in the autoimmune  
attack on the human beta cell which occurs in type I 
diabetes. Rabinovitch et al. (1996) examined the  
relationship between cytokine induced (interleukin 1b, 
tumor necrotic factor (TNF) and interferon gamma) 
pancreatic beta cell destruction, production of 
malondialdehyde (MDA), an end product of lipid  
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peroxidation; and nitrite, the end product of nitric 
oxide. These studies suggested cytokines are toxic to the 
human beta cell by producing oxygen free radicals, 
lipid  
peroxidation, and aldehyde production in the islets 
and that MDA was one of the cytotoxic mediators 
(Sumovski et al., 1992 and Rabinovitch et al., 1996). 
 Zn metallothionein complex in the islet cell provides 
protection against free radicals produced in the cell 
from any cause, and certainly the immune mediated 
cytokine provoked oxidative stress would be a  
significant oxidative stress. The more depleted the 
intracellular Zn stores, the less able the cell is to  
defend itself against this oxidative load. This provides 
a potential mechanism for zinc deficiency to affect 
the progress of type I diabetes. There is also some 
data suggesting that the same mechanism of intracellular 
oxidative load may be responsible for the streptozotocin 
induced experimental diabetes. Zimny et al., (1993) 
have demonstrated induction of metallothionein  
production in the islet cell in response to STZ  
induced -OH radical production. Yang and Cherian 
(1994) demonstrated STZ-induced lipid peroxidation 
and decreased superoxide -dismutase (SOD).  The 
lipid peroxidation was mitigated by pretreatment with 
intraperitoneal Zn to induce increased production of 
metallothionein, although no changes in SOD were 
noted. Metallothionein requires Zn for activation and 
a paucity of Zn would exacerbate the deleterious  
effects of STZ on the islet cell. Roza et al. (1995)  
reported marked decreases in pancreatic SOD and 
catalase antioxidant activity which preceded the loss of 
beta cell function. All of these data suggest a role for 
Zn in the protection of the beta cell against the  
immune mediated free radical attack, but it is not 
clear if this related to the genetic factors in the  
predisposition to diabetes or of the islets itself prior to 
cell destruction. 
In type II diabetes there is no good evidence for  
oxidative stress as a major factor in the  
development of either insulin deficiency or islet cell 
damage, but there is clear evidence for increased  
secretion of insulin, at least early in the progress of 
the disease. Since Zn leaves the cell with insulin, the 
greater secretion of insulin causes cellular depletion of 
Zn. The cell can make more insulin, but it cannot 
make more Zn and, with hyperzincuria, the Zn  
co-secreted is more likely to be excreted and not 
available for re-uptake into the cellular pool. With the 
slow loss of intracellular zinc, the less insulin is  
secreted for a given glucose level and the islet cell 
becomes more vulnerable to all sorts of damage. This 
matches the clinical picture in which, after prolonged 
hyperglycemia and inability of the islet cell to make 
enough insulin to control the glucose, there is a loss 
of islet cell altogether. This provides a mechanism 
by which Zn deficiency may affect the progress of 
type II diabetes (Spreitsma and Schuitemaker, 1994). 
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EFFECTS OF ZINC ON DIABETES MELLITUS 
(SECONDARY COMPLICATIONS) 
While diabetes, particularly type I, as a primary  
event is devastating to the body, it is the long-term 
complications which provide  the  bulk of  the   
economic  and  social  costs Hyperglycemia is a  
major culprit in the development of the microvascular 
complications which include retinopathy, nephropathy,  
neuropathy and the small vessel occlusions as well as 
birth defects including fetal malformations  and  macrosomia.  
In mice made diabetic with STZ there was a 
marked increase in fetal loss and malformation as 
compared with nondiabetic mice. In similar, but 
transgenic mice for the human copper zinc superoxide 
dismutase (Cu-Zn SOD), there were fewer fetal   
malformations than in controls without the gene suggesting 
SOD reduces diabetic embryopathy, presumably by 
reducing oxygen free radicals (Hagay et al., 1995).  
Conclusion  
Diabetes of any type can be a devastating personal 
health problem and is certainly a very significant  
public health problem. It would be nice if there 
were some relatively simple interventions which 
would help ameliorate the damage done by this  
disease, either as the primary problem or by its  
hallmark physiologic signature, hyperglycemia.  
The ubiquitous nature of zinc in physiological systems 
suggests that atypical levels are likely to have many 
biological and clinical effects. The true significance of 
zinc in cellular signaling is just emerging. In this  
context the zinc transporters play an essential role in 
insulin and glucose homeostasis. The inhibition of 
protein tyrosine phosphatases by zinc under physiological 
conditions involving zinc transporter mechanisms has 
widespread implications for understanding insulin resistance 
and disease progression.  
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